← back to search

Sumit Shah

Stanford University · US
Area of research
Surgery · Oncology
Research interest
Research interests include Bladder and Urothelial Cancer Treatments, COVID-19 and healthcare impacts, Renal cell carcinoma treatment, and COVID-19 Clinical Research Studies.
h-index
23
citations
4,786
works
123
NIH funding
primary concept
Medicine
email

Recent publications

Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study
European Urology 2025cited by 8position: middledoi
Telemedicine Trends in Ambulatory Surgical Oncology: A Five-Year Analysis of Visit Volume and Utilization at a High-Volume Academic Center
Annals of Surgical Oncology 2025cited by 3position: lastdoi
Treatment‐Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the <scp>UNITE</scp> Study
Cancer Medicine 2025cited by 2position: middledoi
Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data
European Urology Oncology 2024cited by 7position: middledoi
Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19
JAMA Oncology 2022cited by 62position: middledoi
Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study
Open Forum Infectious Diseases 2022cited by 18position: middledoi
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study
Cancer 2021cited by 82position: middledoi
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
The Lancet 2020cited by 1,798position: middledoi
Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study
Cancer Discovery 2020cited by 138position: middledoi
Remote Oncology Care: Review of Current Technology and Future Directions
Cureus 2020cited by 33position: middledoi
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study
The Lancet Oncology 2019cited by 173position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

James Mitchell · Palo Alto University1 papers (2020–2020)M. Miller · National Heart Lung and Blood Institute1 papers (2025–2025)Byrne Lee · Palo Alto University1 papers (2025–2025) · 1 papers (2025–2025) · 1 papers (2025–2025)Andrew Hendifar · Stony Brook University1 papers (2020–2020)Bart M. Demaerschalk · University of Alabama at Birmingham1 papers (2025–2025)Vijaya Parameswaran · Palo Alto University1 papers (2025–2025)Bradley A. McGregor · Harvard University1 papers (2020–2020) · 1 papers (2025–2025) · 1 papers (2025–2025)